Sekar Kathiresan, Chief Executive Officer at Verve Therapeutics, Inc. (VERV), sold 100,000 shares at $33.02 ($3.4M) on 2022-10-03, disclosed to the SEC on 2022-10-05.
Open-market sale of $3.4M VERV by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $33.02 | 28,911 | $955K | 28.4% |
| 2 | $33.02 | 28,911 | $955K | 28.4% |
| 3 | $34.13 | 11,185 | $382K | 11.3% |
| 4 | $34.13 | 11,185 | $382K | 11.3% |
| 5 | $34.97 | 9,904 | $346K | 10.3% |
| 6 | $34.97 | 9,904 |
| $346K |
| 10.3% |
| Total | $33.65 avg | 100,000 | $3.4M | 100% |
| Filing → |
| VERV | SELL | 2022-07-21 | $1.5M | — | Filing → |
| VERV | SELL | 2022-01-06 | $75K | — | Filing → |
| VERV | SELL | 2021-12-29 | $3.9M | — | Filing → |